30 results match your criteria: "Shakomae Kokorono Clinic[Affiliation]"
Benefit of extending the dosing interval of long-acting antipsychotic injections on schizophrenics with extrapyramidal symptoms.
Psychiatry Clin Neurosci
March 2017
Department of Psychiatry, Tokai University School of Medicine, Kanagawa, Japan.
Comparison of Treatment Retention Between Risperidone Long-Acting Injection and First-Generation Long-Acting Injections in Patients With Schizophrenia for 5 Years.
J Clin Psychopharmacol
August 2016
Department of Psychiatry Suzuki Clinic Tokyo, Japan Department of Psychiatry Fukui Kinen Hospital Kanagawa, Japan Department of Psychiatry Shakomae Kokorono Clinic Tokyo, Japan Department of Psychiatry Fukui Kinen Hospital Kanagawa, Japan.
Comparison of hospitalization risk before and after changing from risperidone long-acting injection to another long-acting injection or oral antipsychotic in patients with schizophrenia: Mirror-image study.
Psychiatry Clin Neurosci
August 2016
Department of Psychiatry, Shakomae Kokorono Clinic, Tokyo, Japan.
Changes in length of hospital stay before and after the administration of a long-acting injection in patients with schizophrenia: Mirror-image study.
Psychiatry Clin Neurosci
June 2016
Department of Psychiatry, Shakomae Kokorono Clinic, Tokyo, Japan.
The influence and changes in the dosages of concomitantly used psychotropic drugs associated with the discontinuation of donepezil in severe Alzheimer's disease with behavioral and psychological symptoms on dementia: a preliminary open-label trial.
Ther Adv Psychopharmacol
February 2014
Department of Psychiatry, Seimo Hospital, Gunma, Japan.
Objective: We investigated the influence on behavioral and psychological symptoms on dementia (BPSD) and the changes in the dosages of concomitant psychotropic drugs associated with the discontinuation of donepezil in patients with severe Alzheimer's disease (AD) who developed BPSD during donepezil therapy.
Methods: The subjects were 44 inpatients who had been diagnosed with AD according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV). The outcome measures assessed were BPSD and cognitive function.